Global Colorectal Cancer Market growing at a CAGR of 3.7% from 2023 to 2031
Category : Pharmaceuticals And Healthcare | Published Date : Nov 2023
Key Market Overview
Consegic Business Intelligence analyzes that the colorectal cancer market is predicted to grow at a compound annual growth rate of 3.7% from 2023 to 2031 and is expected to reach USD 26,111.69 million in 2031 and 19,530.85 million in 2023 which was valued at USD 18,944.00 million in 2022.
The report highlights the significant increase in awareness of mental health across the globe, which is augmenting the global market growth. Consegic Business Intelligence study also provides insights into the market's competitive landscape, market segmentation, regional outlook, and emerging technologies in the colorectal cancer market.
Global Colorectal Cancer Market By Overview
The colorectal cancer market is bifurcated into type, diagnosis type, treatment, and end user. Based on type, the market is segmented into adenocarcinoma, carcinoid tumors, squamous cell carcinoma, gastrointestinal stromal tumors (GISTs), and others. In 2022, the adenocarcinoma segment dominated the overall colorectal cancer market. Based on diagnosis type, the market is categorized into stool examination, imaging test, tumor markers, biopsy, and others. In 2022, the biopsy segment accounted for the highest market share in the colorectal cancer market. Based on treatment, the market is categorized into chemotherapy, targeted therapy, radiation therapy, surgery, immunotherapy, embolization, and others. In 2022, the chemotherapy segment accounted for the highest market share in the colorectal cancer market. Based on end user, the market is categorized into hospitals, specialty clinics, cancer research centers, ambulatory surgical centers, and others. In 2022, the hospitals segment accounted for the highest market share in the colorectal cancer market.
Get Free SampleMarket Dynamics
Driver:
- Increasing prevalence of colorectal cancer is driving the market growth.
- Increasing innovation in chemotherapy drugs is propelling market growth.
Restraints:
- The high cost of chemotherapy and immunotherapy drugs may hamper the market growth.
Market Segmentation:
| Report Attributes | Report Details |
| By Type | Adenocarcinoma, Carcinoid Tumors, Squamous Cell Carcinoma, Gastrointestinal Stromal Tumors (GISTs), and Others |
| By Diagnosis Type | Stool Examination, Imaging Test, Tumor Markers, Biopsy, and Others |
| By Treatment | Chemotherapy, Targeted Therapy, Radiation Therapy (External Beam Radiation Therapy (EBRT) and Brachytherapy), Surgery, Immunotherapy, Embolization, and Others |
| By End User | Hospitals, Specialty Clinics, Cancer Research Centers, Ambulatory Surgical Centers, and Others |
| By Region | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Competitive Landscape :
The market is dominated by certain major companies such as Pfizer, Sanofi, Bayer, among others which have a strong market position in the current market circumstances. These companies are continuously leveraging new technologies to develop innovative solutions. Furthermore, the colorectal cancer market is expected to witness substantial growth in the coming years due to the increasing availability of minimally invasive surgical procedures for colorectal cancer treatment. The market is characterized by intense competition, with companies focusing on expanding their product offerings and increasing their market share through mergers, acquisitions, and partnerships.
- Pfizer
- Sanofi
- Genentech USA, Inc.
- Merck & Co., Inc
- Eli Lilly and Company
- TAIHO ONCOLOGY, INC.
- Epigenomics Inc.
- Bayer
- Bristol-Myers Squibb Company
- GSK